This functionality is implemented using Javascript. It cannot work without it, etc...

Estamos cargando la información...

Saltar al contenido

Políticas Médicas

Las políticas médicas son documentos que definen el reconocimiento de cubierta para tecnologías, procedimientos y tratamientos. Las declaraciones de necesidad médica en las políticas, sobre si una tecnología, procedimiento, tratamiento, suplido, equipo, medicamento u otro servicio mejora el resultado en la salud de la población para la cual dicha tecnología o tratamiento fue diseñado se basan en evidencia científica, estudios clínicos y opiniones profesionales de nuestros proveedores y de las organizaciones médicas reconocidas.

Cada documento desplegado en este sitio Web se provee con propósitos informativos solamente y no es una autorización, explicación de beneficios o un contrato. El recibir beneficios está sujeto a la satisfacción de todos los términos y condiciones de la cubierta. La tecnología médica cambia constantemente y nos reservamos el derecho de revisar y actualizar nuestras políticas periódicamente.

ID Título Última Revisión Siguiente Revisión Descripción Acceso
07.001.066 Risk-Reducing Mastectomy Oct 07, 2024 Aug 20, 2025 Risk-reducing mastectomy is defined as the removal of the breast in the absence of malignant disease to... Ver
11.003.027 Gene Variants Associated With Breast Cancer In Individuals At High Breast Cancer Risk. Sep 12, 2024 Sep 20, 2025 It is estimated that 3% to 5% of women presenting for assessment for hereditary breast/ovarian cancer risk... Ver
11.003.030 Genetic Testing For Brca1 Or Brca2 For Hereditary Breast/Ovarian Cancer Syndrome And Other High-Risk Cancers Feb 10, 2025 Sep 20, 2025 Hereditary breast and ovarian cancer syndrome describe the familial cancer syndromes related to variants in... Ver
11.003.036 Genetic Testing For Familial Cutaneous Malignant Melanoma Apr 18, 2025 Apr 20, 2026 Cutaneous melanoma is the third most common type of skin cancer, but the most lethal. some cases of cutaneous... Ver
11.003.048 Carrier Screening For Genetic Diseases Oct 10, 2024 Oct 20, 2025 Carrier screening is performed to identify individuals at risk of having offspring with inherited recessive... Ver
11.003.064 Genetic Cancer Susceptibility Panels Using Next Generation Sequencing Dec 12, 2024 Nov 20, 2025 Commercially available cancer susceptibility gene panels can test for multiple variants associated with a... Ver
11.003.098 Use Of Common Genetic Variants (Single Nucleotide Variants) To Predict Risk Of Nonfamilial Breast Cancer Nov 15, 2024 Nov 20, 2025 Several single nucleotide variants (snvs), which are single base-pair variations in the dna sequence of the... Ver
11.003.107 Genetic Testing For Hereditary Pancreatic Cancer Mar 03, 2025 Mar 20, 2026 Pancreatic cancer is the fourth leading cause of cancer death in the united states, accounting for 8.3% of... Ver
11.003.134 Molecular Testing For Variants Associated With Hereditary Ovarian Cancer Dec 16, 2024 Sep 20, 2025 It is estimated that approximately 20% of women presenting for assessment for hereditary ovarian cancer (oc)... Ver
11.003.135 Germline and Somatic Biomarker Testing (Including Liquid Biopsy) for Targeted Treatment and Immunotherapy in Breast Cancer Jan 20, 2025 Jan 20, 2026 Multiple biomarkers are being evaluated to predict response to targeted treatments for patients with advanced... Ver
11.003.137 Germline Genetic Testing for Hereditary Diffuse Gastric Cancer (CDH1, CTNNA1) Sep 20, 2024 Sep 20, 2025 Hereditary diffuse gastric cancer (hdgc, sometimes called signet ring gastric cancer) is an autosomal... Ver
11.003.138 Germline and Somatic Biomarker Testing (Including Liquid Biopsy) for Targeted Treatment and Immunotherapy in Prostate Cancer (BRCA1/2, Homologous Recombination Repair Gene Alterations, Microsatellite Instability/Mismatch Repair, Tumor Mutational Burden) Oct 08, 2024 Oct 20, 2025 Biomarker-targeted therapy has shown a clear survival benefit in individuals with metastatic prostate cancer.... Ver
11.003.139 Germline and Somatic Biomarker Testing (Including Liquid Biopsy) for Targeted Treatment and Immunotherapy in Ovarian Cancer (BRCA1, BRCA2, Homologous Recombination Deficiency, Tumor Mutational Burden, Microsatellite Instability/Mismatch Repair) Oct 16, 2024 Oct 20, 2025 Biomarker-targeted therapy has shown a clear survival benefit in patients with ovarian cancer. more recently,... Ver

¿Quieres estar al día con temas sobre salud, noticias, consejos, estilo de vida y más?

¡Suscríbete a nuestro blog para que no te pierdas de nada!

Suscribirse al blog

Queremos personalizar los contenidos de acuerdo a tus preferencias

Por favor selecciona una o más categorias para continuar

¡Gracias por tu suscripción!

Recibirás en tu correo información de tu interés.

787-277-6653 787-474-6326